tiprankstipranks
Trending News
More News >
Proteome Sciences PLC (GB:PRM)
LSE:PRM
Advertisement

Proteome Sciences (PRM) AI Stock Analysis

Compare
2 Followers

Top Page

GB:PRM

Proteome Sciences

(LSE:PRM)

Rating:41Neutral
Price Target:
2.50p
▼(-12.28% Downside)
Proteome Sciences exhibits significant financial instability, with declining revenues, negative profitability, and high debt levels being the most impactful factors. The technical analysis indicates a bearish trend, and the valuation metrics are unattractive due to negative earnings. These factors collectively result in a low overall stock score.

Proteome Sciences (PRM) vs. iShares MSCI United Kingdom ETF (EWC)

Proteome Sciences Business Overview & Revenue Model

Company DescriptionProteome Sciences (PRM) is a biotechnology company that specializes in the analysis of proteins and their roles in biological processes. The company focuses on proteomics, offering advanced technologies and services for the identification, quantification, and characterization of proteins. Its core products include proprietary assays, software solutions, and analytical services that cater to research institutions, pharmaceutical companies, and biotech firms, facilitating drug discovery and development.
How the Company Makes MoneyProteome Sciences generates revenue primarily through the sale of its proteomic services and products. Key revenue streams include contract research services for pharmaceutical and biotechnology companies, where they provide custom proteomics analysis and biomarker discovery services. Additionally, the company earns income from licensing its proprietary technologies and tools to other firms in the industry. Significant partnerships with academic institutions and collaborations with industry leaders also contribute to its earnings, as they often lead to joint research initiatives and shared funding opportunities.

Proteome Sciences Financial Statement Overview

Summary
Proteome Sciences is facing substantial financial challenges across all financial statements. Declining revenues, negative profitability, and high debt levels indicate significant business risks. The negative equity and cash flow issues further exacerbate the company's financial instability.
Income Statement
20
Very Negative
The company has experienced declining revenue with a decrease from 5.03 million to 4.89 million over the last year, indicating a negative revenue growth rate. The negative EBIT and net income margins highlight ongoing operational challenges with profitability. These factors indicate financial instability in the income statement.
Balance Sheet
10
Very Negative
The company has a negative stockholders' equity, indicating that liabilities exceed assets, which is a significant concern. The debt-to-equity ratio cannot be calculated due to negative equity, but the high total debt level suggests potential solvency issues. This balance sheet position suggests high financial risk.
Cash Flow
15
Very Negative
Operating cash flow is negative, and free cash flow has worsened, indicating cash flow difficulties. The free cash flow to net income ratio is negative, reflecting challenges in generating cash relative to net income. These factors demonstrate weak cash flow management.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue4.89M5.03M23.74B22.59B16.95B
Gross Profit670.00K1.65M23.73B22.59B16.94B
EBITDA-1.51M-1.14M1.83M625.00K714.00K
Net Income-3.41M-2.44M1.32M72.00K295.00K
Balance Sheet
Total Assets9.21M11.46M12.43M10.04M9.09M
Cash, Cash Equivalents and Short-Term Investments1.13M2.03M3.99M2.39M2.21M
Total Debt14.52M13.47M11.91M11.69M11.04M
Total Liabilities15.72M14.52M13.28M12.82M12.45M
Stockholders Equity-6.52M-3.07M-843.00K-2.77M-3.36M
Cash Flow
Free Cash Flow-1.05M-718.00K2.14B8.80B-9.07B
Operating Cash Flow-826.00K-481.00K3.88B10.52B-7.74B
Investing Cash Flow-224.00K-424.00K-21.67B4.27B-18.38B
Financing Cash Flow151.00K-1.06M27.05B38.50B67.98B

Proteome Sciences Technical Analysis

Technical Analysis Sentiment
Positive
Last Price2.85
Price Trends
50DMA
3.04
Positive
100DMA
3.15
Negative
200DMA
3.42
Negative
Market Momentum
MACD
>-0.01
Negative
RSI
55.86
Neutral
STOCH
59.48
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:PRM, the sentiment is Positive. The current price of 2.85 is below the 20-day moving average (MA) of 3.02, below the 50-day MA of 3.04, and below the 200-day MA of 3.42, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 55.86 is Neutral, neither overbought nor oversold. The STOCH value of 59.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:PRM.

Proteome Sciences Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
64
Neutral
£11.35M-13.85%7.27%39.64%
59
Neutral
£11.62M-62.83%27.60%1.35%
51
Neutral
$7.81B-0.22-40.01%2.29%21.48%-2.11%
51
Neutral
£4.84M-321.90%125.37%22.47%
46
Neutral
£9.30M-333.59%45.22%55.71%
46
Neutral
£4.02M-367.05%25.05%65.30%
41
Neutral
£8.86M
-2.80%-38.55%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
GB:PRM
Proteome Sciences
2.85
-0.51
-15.18%
GB:GDR
Genedrive
0.78
-1.74
-69.05%
GB:IXI
IXICO plc
12.25
2.75
28.95%
GB:OBD
Oxford BioDynamics
0.48
-5.75
-92.30%
GB:ABDX
Abingdon Health PLC
5.25
-5.00
-48.78%
GB:GENI
GENinCode UK Ltd.
1.40
-5.35
-79.26%

Proteome Sciences Corporate Events

Shareholder MeetingsBusiness Operations and Strategy
Proteome Sciences Announces Successful AGM Resolutions
Positive
May 16, 2025

Proteome Sciences announced that all resolutions were passed at their Annual General Meeting, indicating strong shareholder support and a stable governance structure. This outcome reinforces the company’s strategic direction and could positively impact its market position in the proteomics industry, benefiting stakeholders by ensuring continued focus on innovative drug discovery and biomarker identification services.

Shareholder MeetingsBusiness Operations and Strategy
Proteome Sciences Sees Strong Recovery and Growth Prospects
Positive
May 16, 2025

At its Annual General Meeting, Proteome Sciences announced a continued recovery in the pharmaceutical and biotech markets, with a strong pipeline of orders extending into 2026. The company is progressing with licensing discussions for new DXT tags and has completed its first commercial single cell proteomics project. The increased demand has led to full capacity utilization at their Frankfurt site, positioning the company for substantial future revenue growth.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 29, 2025